- Home
- AXTA vs MDGL Comparison
AXTA vs MDGL Comparison
Compare AXTA & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXTA
- MDGL
- Stock Information
- Founded
- AXTA 1910
- MDGL 2011
- Country
- AXTA United States
- MDGL United States
- Employees
- AXTA N/A
- MDGL N/A
- Industry
- AXTA Paints/Coatings
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- AXTA Consumer Discretionary
- MDGL Health Care
- Exchange
- AXTA Nasdaq
- MDGL Nasdaq
- Market Cap
- AXTA 6.2B
- MDGL 9.6B
- IPO Year
- AXTA 2014
- MDGL N/A
- Fundamental
- Price
- AXTA $28.24
- MDGL $560.16
- Analyst Decision
- AXTA Buy
- MDGL Strong Buy
- Analyst Count
- AXTA 14
- MDGL 13
- Target Price
- AXTA $37.36
- MDGL $529.00
- AVG Volume (30 Days)
- AXTA 4.5M
- MDGL 425.2K
- Earning Date
- AXTA 10-28-2025
- MDGL 11-04-2025
- Dividend Yield
- AXTA N/A
- MDGL N/A
- EPS Growth
- AXTA 40.67
- MDGL N/A
- EPS
- AXTA 2.09
- MDGL N/A
- Revenue
- AXTA $5,166,000,000.00
- MDGL $740,640,000.00
- Revenue This Year
- AXTA N/A
- MDGL $395.75
- Revenue Next Year
- AXTA $2.24
- MDGL $65.73
- P/E Ratio
- AXTA $13.38
- MDGL N/A
- Revenue Growth
- AXTA N/A
- MDGL 864.21
- 52 Week Low
- AXTA $26.28
- MDGL $265.00
- 52 Week High
- AXTA $41.66
- MDGL $577.90
- Technical
- Relative Strength Index (RSI)
- AXTA 45.21
- MDGL 74.90
- Support Level
- AXTA $27.45
- MDGL $505.00
- Resistance Level
- AXTA $29.85
- MDGL $544.25
- Average True Range (ATR)
- AXTA 0.81
- MDGL 30.01
- MACD
- AXTA -0.01
- MDGL 10.02
- Stochastic Oscillator
- AXTA 28.25
- MDGL 90.72
About AXTA Axalta Coating Systems Ltd.
Axalta Coating Systems Ltd is a manufacturer, marketer and distributor of high-performance coatings systems. It operates in two segments, The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial. The Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The company operates in the geographic areas of North America, EMEA countries, Asia-Pacific, and Latin America.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.